title: Carrier-free functionalized multidrug nanorods for synergistic cancer therapy.
abstract: We developed carrier-free multidrug nanocrystals (MDNCs) for the combination chemotherapy with synergistic effect, improved tolerance and imaging capability for cancer treatment. Three widely used hydrophobic drugs, methotrexate (MTX), 10-hydroxycamptothecin (HCPT) and paclitaxel (PTX), were prepared into one nanorod, and then conjugated with poly(ethylene glycol) (PEG) to improve their water dispersity and bio-environmental stability. It should be noted that only trace amount of PEG was used for surface modification, which ensures a high drug loading capacity of the resulting PEGylated MDNCs. In vitro studies showed that the MDNCs revealed an obviously higher cytotoxicity than individual drugs in the same dose and suppressed drug resistance against PTX resistant MCF-7/ADR cancer cells, indicating its synergistic effect and improved tolerance. After in vivo intravenous injection, the MDNCs exhibits a synergetic in vivo therapeutic effect and possesses obviously superior antitumor effect compared to free multidrugs treatment group and individual drug treatment groups, and no statistically significant weight loss was observed. The MDNCs can also gain imaging capabilities by encapsulated with an organic dye, which render the multidrug nanorod an all-in-one processing system for cancer diagnosis and treatment.
authors: Functional Nano & Soft Materials Laboratory, Soochow University, 199 Ren-Ai Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, PR China.
authors: Mengjiao
authors: M
authors: Zhou
authors: Xiujuan
authors: X
authors: Zhang
authors: Yinlong
authors: Y
authors: Yang
authors: Zhuang
authors: Z
authors: Liu
authors: Baishun
authors: B
authors: Tian
authors: Jiansheng
authors: J
authors: Jie
authors: Xiaohong
authors: X
authors: Zhang
mesh_terms: D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000379:methods*; D006367:HeLa Cells; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007624:KB Cells; D061986:MCF-7 Cells; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D043942:Nanotubes / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000494:pharmacology
chemical_list: D004337:Drug Carriers; C028098:10-hydroxycamptothecin; D017239:Paclitaxel; D002166:Camptothecin; D008727:Methotrexate
keywords: 10-Hydroxycamptothecin; Drug delivery; Methotrexate; Multidrug nanocrystals; Paclitaxel; Poly(ethylene glycol)methyl ethers